Member Info for Fadec92

Doesn’t that give a potential license holder the option in what to progress giving us the versatility for a better deal while party’s carry out the best choice at that point with more data reads outs of the competition, I don’t really mind an indication not being chosen because it dosnt matter whether it be lupus, Crohn's disease, RA, asthma and viral bacteria infections what does it matter the focus is set on SDC-1801 autoimmune that’s clear enough, and it does maybe indicate that they are thinking of a deal preclinical, the molecule dosnt have to changed or the manufacturing process!

Roxbury it looks like you should have researched more about the company, listening to every Tom, dick and Harry should have not been your investment strategy, T Sen is the lady your talking off, and has published an a academic paper on SRA737 and Gemcitbine and Pd-1 Keytruda the paper showed the potential of SRA737 in combo and is very inciting, especially linked to other indications, but needs everyone to start playing ball, and your right it did seam that a lot of posts seam like they are clutching at straws when listening to them, you need to have your own base of research and confidence in the company!

Steve Sareum are not going to have something better than a vaccine, they have kinases that inhibit the immune response in reaction to an over reaction by inhibiting the right IL’s Interleukins connected by the ailment in the nature of inflammation whether it by lupus, Crohn's disease, RA, asthma and viral bacteria infections, so it’s not prevention like a vaccine but would be in response too so you couldn’t have a secondary molecule working better than it!

308 it was over 70 yesterday, can I ask why is 70 support?

I think it would be unfair to look for another ceo too take forward even though I understand that investors are tired and some would like a deal now as they have had enough time to deliver, but myself would like preclinical done first and at least an application for trials which I think is said to be at the end of the year, they are a small company with hardly any cash so cannot see great expectations when still in preclinical, I would agreed Utah the raise in share price ie covid19 but haven’t had any meat on the bones and would have expected more news related to this so as I thought from the beginning with the extra normal PR!

Formulation issue would have to be solved for the compound first let alone phase 2 trials, also the small molecules that Sareum produce are not vaccines!

Thanks Krone would have thought it means ICR and Sareum’s as they are the stakeholders in SRA737, that’s pretty black and white suspended development, I don’t think that’s been said before other than with total exclusion of SRA737 in Sierra’s RNS’s!

Preclinical is still in process, deal time would be late preclinical early clinical as is written in the RNS’s and verbally by Tim in interviews!

Hi all the Triparna Sen goes back a while and we were all very excited about it and just before the ASCO last June was the research presented, she did a presentation last November too for Sierra but nothing since that!

https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=sra737

He’s been brought into commercialize momelotinib, so I wouldn’t expect a change of development from this too SRA737, a lot of unanswered questions we know nothing and it dosnt seam good from our point of view, even dropped trying to find a non-dilutive partner, looks like they will probably look to drag it further, I wonder what ICR are going to do about it, unbelievable!

Bullish trend intact, volume rising and coming off nicely today with a good recovery, I loved how the mm’s dropped a delayed 20k trade from the day before at 11.15 and at the same time dropping the bid to the same sell level @ 0.65 to spook people to sell and worked for one, then cancelled the 20k later on, the tricks they pull!

Hi all Sareums molecules do inhibit JAK2 on SDC-1801 the IC50 of JAK2 is 26nM and the IC50 of JAK1 is 23nM so JAK2 is slightly less than JAK1!

What’s a little more dilution to have a better position hand in negotiations, I would rather a bigger deal as it’s been a number of years for me, so another year and a raise would not concern me to firm up the position, I don’t think it’s beneficial too just get it done at all costs now, they have always said it late pre-clinical early clinical, the only way small companies have at their disposal is too raise cash of share offerings as there is too much risk involved with early stage biotech, and it’s not as if they have been extravagant like most companies on aim raising left right and center they do in my mind seam quite sensible in cash resources!

It’s an old publication, the research that forms part of the article on DNA Damage molecules which they refer too is from 2011 I think this article has a date on top of 2019 and 2018 :-

Anticancer Therapy With Checkpoint Inhibitors: What, Where and When?
Michelle D Garrett et al. Trends Pharmacol Sci. 2011 May.

The reference to the CHK1 inhibitor as that identifying code dosnt exist anymore it changed to SRA737 so it’s old!

Aber it must be a hard decision to make, as a grant RNS could come any day, and I’m sure that would mess their plan!

I’m sure UK will be doing a similar setup!

FDA issues two guidances to accelerate Covid-19 treatments

“The FDA on Monday evening issued two guidances intended to accelerate the development of products to treat or prevent coronavirus disease (Covid-19), laying out recommendations to help companies get to the investigational new drug application (IND) stage and clinical trial design considerations for later-stage studies.“

“FDA says the guidance is focused on the development of direct antiviral drugs or products with immunomodulatory activity”

https://endpts.com/fda-issues-two-guidances-to-accelerate-covid-19-treatments/

Cytokine-Targeted Therapy in Severely ill COVID-19 Patients

https://www.ejmo.org/pdf/Cytokinetargeted%20therapy%20in%20severely%20ill%20COVID19%20patients%20Options%20and%20cautions-72142.pdf

Hi Stoney that’s what I’ve been saying, it’s a generic tweet not made directly by the company but a hired public relations company, you find they post it once we have here! The ones the companies will directly tweet will usual be the highly relevant ones, like the one in Jan/feb of the TYK2 I’m Cancer Publication or again might still be PR, i like too think they don’t have the time too observe the internet looking for links, but are gathering evidence why SDC-1801 would be a good fit molecule for the cytokine storm and over active inflammation and the application!

Hi Stoney couldn’t get that link! Thumbs up!

“Among 41 patients with laboratory-confirmed COVID-19 pneumonia described by Huang and colleagues, the 13 patients requiring intensive care showed significantly higher serum levels of many cytokines and chemokines including IL-2, IL-7, IL-10, G-CSF, TNF-a, and IL-1Ra compared to those who were not in an intensive care unit (ICU). In comparison to healthy controls they also showed higher serum levels of IL-6, IL-9, IL-13, GM-CSF, IFN-?, IL-1ß, IL-8, and IL-17.

In a study of 50 COVID-19 patients, Hadjadj et al. found an increase in peripheral blood of IL-6 and IL-6-induced genes, TNF-a and TNF-a pathway-related genes, as well as IL-10.

Therefore, the use of Janus kinase (JAK) inhibitors (JAKi) targeting IL-6 and other cytokines with JAK-dependent signaling is one way to restrain the excessive level of cytokine signaling.”

https://immunology.sciencemag.org/content/5/47/eabc5367

It’s a different than JAK/Stat type or method by blocking certain Interleukins, a receptor antagonist binds a receptor ligands, all depends which, these ones block the :-

IL-1, IL-6, IL-18, and interferon ?

In the presentation it mentions IL-1ß - GM-CSF pathway blocked by virally-induced IFNa and IFN? until more knowledge is brought forward about what benefits JAK/Tyk2 then can compare more!